PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2

Starting soon · Not applicable

Conditions studied: Coronary Artery Disease

In brief

The PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite outcome of cardiac death, target-vessel myocardial infarction (MI), unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years, compared with an initial conservative strategy of optimal medical therapy (OMT) alone, in patients with high-risk vulnerable plaque identified by coronary computed tomography angiography (CCTA).

Key facts

Study ID

NCT07569692

Run by

Seung-Jung Park

People needed

2500

Starts

2026-07-30

Expected to finish

2031-12-31

Last updated by the study team

2026-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged ≥18 years
• Patients with suspected coronary artery disease (CAD) (e.g., chest pain syndrome or equivalent symptoms) who are evaluated with coronary computed tomography angiography (CCTA)
• Coronary computed tomography angiography (CCTA) showing:
• Plaque with at least moderate stenosis in one or more major epicardial coronary arteries; and
• At least two high-risk plaque (HRP) feature at the site of stenotic lesions, defined as any of the following:
• Low-attenuation plaque (LAP) (<70 Hounsfield units)
• Positive remodeling (PR) (remodeling index >1.2)
• Napkin-ring sign (NRS)
• Spotty calcification (SC) (<3 mm in length)
• Willing and able to provide written informed consent

You may not qualify if…

• Acute coronary syndrome (ACS) requiring urgent or emergent invasive evaluation
• Hemodynamically unstable conditions
• Significant left main coronary artery disease (≥50% diameter stenosis)
• Coronary anatomy unsuitable for either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
• Left ventricular ejection fraction (LVEF) <35%
• → Left ventricular ejection fraction <35%
• New York Heart Association (NYHA) class III or IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months
• Prior coronary artery bypass grafting (CABG)
• Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m²) or end-stage renal disease on dialysis
• Contraindication to undergoing coronary computed tomography angiography (CTA) (e.g., allergy to radiographic contrast that cannot be adequately premedicated, any prior anaphylaxis to radiographic contrast, or inability to cooperate with scan acquisition)
• Contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year
• Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity
• Planned cardiac or major noncardiac surgery within the study period
• Women who are breastfeeding, pregnant, or planning to become pregnant during the course of the study
• Inability to comply with the study protocol
• Active participation in another interventional clinical trial involving an unapproved investigational drug or device

Where it is running

• Asan Medical Center — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.